The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SPRO | +188.66% | -85.35% | -31.87% | -79% |
| S&P | +16.89% | +84.17% | +12.98% | +169% |
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
The small biopharma's work has captured the attention of a much bigger player.
The pricing of a stock offering is causing the drugmaker's shares to fall.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.05M | -61.0% |
| Gross Profit | $6.02M | 0.0% |
| Gross Margin | 99.97% | 0.0% |
| Market Cap | $105.80M | 46.1% |
| Market Cap / Employee | $3.31M | 0.0% |
| Employees | 32 | 0.0% |
| Net Income | -$7,382.00K | 56.9% |
| EBITDA | -$9,723.00K | 59.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $48.62M | -36.3% |
| Accounts Receivable | $868.00K | -98.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.45M | -49.6% |
| Short Term Debt | $1.90M | 9.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -46.31% | -49.2% |
| Return On Invested Capital | -59.38% | -12.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $17.42M | 36.5% |
| Operating Free Cash Flow | $17.42M | 36.5% |
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 3.91 | 3.88 | 16.88 | - | |
| Price to Book | 0.85 | 0.85 | 4.79 | 3.22 | 257.92% |
| Price to Sales | 2.05 | 1.41 | 4.77 | 3.61 | 347.20% |
| Price to Tangible Book Value | 0.85 | 0.85 | 4.79 | 3.22 | 257.92% |
| Enterprise Value to EBITDA | -0.29 | 0.33 | -28.41 | -6.23 | 17464.96% |
| Return on Equity | -89.6% | -107.3% | -94.6% | -95.3% | -1716.43% |
| Total Debt | $4.30M | $3.96M | $3.62M | $3.35M | -27.50% |
No podcast episodes available.
SPRO earnings call for the period ending September 30, 2020.
SPRO earnings call for the period ending June 30, 2020.
SPRO earnings call for the period ending March 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
